174 related articles for article (PubMed ID: 38499168)
21. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.
Thomas LW; Lee EB; Wu JJ
J Dermatolog Treat; 2019 Mar; 30(2):110-116. PubMed ID: 29737896
[TBL] [Abstract][Full Text] [Related]
22. Japanese guidance for use of biologics for psoriasis (the 2019 version).
Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
[TBL] [Abstract][Full Text] [Related]
23. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review.
Hwang JK; Ricardo JW; Lipner SR
Am J Clin Dermatol; 2023 Sep; 24(5):695-720. PubMed ID: 37209391
[TBL] [Abstract][Full Text] [Related]
25. Biologics in the treatment of pustular psoriasis.
Wang WM; Jin HZ
Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
[TBL] [Abstract][Full Text] [Related]
26. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and skin clearance recapture in clinical studies of brodalumab.
Bagel J; Lebwohl M; Israel RJ; Jacobson A
J Am Acad Dermatol; 2020 Feb; 82(2):344-351. PubMed ID: 31175910
[TBL] [Abstract][Full Text] [Related]
28. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
Mastorino L; Dapavo P; Susca S; Cariti C; Siliquini N; Verrone A; Stroppiana E; Ortoncelli M; Quaglino P; Ribero S
J Dtsch Dermatol Ges; 2024 Jan; 22(1):34-42. PubMed ID: 37926830
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
Zhang Z; Schmitt J; Wozel G; Kirch W
Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
[TBL] [Abstract][Full Text] [Related]
30. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
31. Biologics switch in psoriasis.
Wang TS; Tsai TF
Immunotherapy; 2019 Apr; 11(6):531-541. PubMed ID: 31135243
[No Abstract] [Full Text] [Related]
32. Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
Leonardi CL; See K; Burge R; Sun Z; Zhang Y; Mallbris L; Garrelts A; Warren RB
Adv Ther; 2022 May; 39(5):2256-2269. PubMed ID: 35316500
[TBL] [Abstract][Full Text] [Related]
33. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Huang IH; Wu PC; Chiu HY; Huang YH
Am J Clin Dermatol; 2024 May; 25(3):347-358. PubMed ID: 38438782
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection.
Heron CE; Ghamrawi RI; Balogh EA; Feldman SR
Am J Clin Dermatol; 2021 Mar; 22(2):221-231. PubMed ID: 33169802
[TBL] [Abstract][Full Text] [Related]
36. Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study.
Kishimoto M; Komine M; Kamiya K; Sugai J; Kuwahara A; Mieno M; Ohtsuki M
Dermatol Ther (Heidelb); 2023 Jun; 13(6):1347-1360. PubMed ID: 37204609
[TBL] [Abstract][Full Text] [Related]
37. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Armstrong AW; Read C
JAMA; 2020 May; 323(19):1945-1960. PubMed ID: 32427307
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
Reich K; Blauvelt A; Armstrong A; Langley RG; de Vera A; Kolbinger F; Spindeldreher S; Ren M; Bruin G
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1733-1741. PubMed ID: 31009130
[TBL] [Abstract][Full Text] [Related]
40. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response.
Hsu L; Armstrong AW
Expert Rev Clin Immunol; 2013 Oct; 9(10):949-58. PubMed ID: 24128157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]